In this episode, guest Emma Guttman-Yassky, MD, PhD, discusses inflammatory diseases, the association between JAK inhibition and Down syndrome comorbidities and more. •    Intro 0:26 •    Emma Guttman-Yassky, MD, PhD 0:33 •    What is your new research in alopecia areata about, and what dermatologists should know about using dupilumab (Dupixent; Regeneron, Sanofi) in children with alopecia areata? 1:06 •    Have you tried any other drugs to target IL-13?  3:21 •    Do you think any of the currently available IL-13 targeting drugs would be useful in this setting, or do you need IL-4 targeting drugs as well?  4:22 •    Can you give some insight on the work you are doing surrounding the association between JAK inhibitors and patients with Down syndrome?  5:20 •    Do you think that the type of psoriasis we see in patients with Down syndrome may be amenable to JAK inhibitors? 6:35 •    What are some of your top tips for people who are or want to be leaders in this specialty in order to be successful? 7:53 •    Thank you, Dr. Guttman. 9:41 Emma Guttman-Yassky, MD, PhD, is the Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology and director of the Center of Excellence in Eczema and the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai as well as a member of the Healio Allergy/Asthma Peer Perspective Board.

We’d love to hear from you! Send your comments/questions to Dr. Gelfand at [email protected]. Follow Dr. Gelfand on LinkedIn.

For more, be sure to visit the Beneath the Surface video blog on Healio.com. 

Disclosures: Gelfand reports no relevant financial disclosures. Guttman-Yassky reports having financial relationships with AbbVie, Almirall, Amgen, AnaptysBio, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Innovaderm, Janssen Biotech, Kyowa Kirin, LEO Pharma, Novartis, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB and Ventyx Biosciences.